Inventor · disambiguated record
Ved P. Srivastava
Also filed as: SRIVASTAVA VED · SRIVASTAVA VED P
15 granted patents·9 pending applications·116 citations·filing 2005–2025
91Inventor score
Files withINTARCIA THERAPEUTICS INC7AMYLIN PHARMACEUTICALS INC4I2O THERAPEUTICS INC4LEVY ODILE ESTHER4AMYLIN PHARMACEUTICALS LLC2
Top patents by PatentIndex Score
24 records- 0196US8263545B2GIP analog and hybrid polypeptides with selectable propertiesLEVY ODILE ESTHER·Filed 2007·Granted Sep 11, 2012·62 cites·3 claims
- 0295US8497240B2DPP-IV resistant GIP hybrid polypeptides with selectable propertiesLEVY ODILE ESTHER·Filed 2007·Granted Jul 30, 2013·25 cites·11 claims
- 0390US11840559B2Glucagon-receptor selective polypeptides and methods of use thereofINTARCIA THERAPEUTICS INC·Filed 2021·Granted Dec 12, 2023·1 cites·19 claims
- 0490US8404637B2GIP analog and hybrid polypeptides with selectable propertiesLEVY ODILE ESTHER·Filed 2006·Granted Mar 26, 2013·16 cites·12 claims
- 0589US11739134B2Long acting peptide tyrosine tyrosine (PYY) analogs and methods of useINTARCIA THERAPEUTICS INC·Filed 2021·Granted Aug 29, 2023·2 cites·20 claims
- 0687US11214607B2Glucagon-receptor selective polypeptides and methods of use thereofINTARCIA THERAPEUTICS INC·Filed 2019·Granted Jan 4, 2022·3 cites·20 claims
- 0784US10501517B2Glucagon-receptor selective polypeptides and methods of use thereofINTARCIA THERAPEUTICS INC·Filed 2017·Granted Dec 10, 2019·4 cites·61 claims
- 0880US2024239861A1Glucagon-receptor selective polypeptides and methods of use thereofI2O THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0975US12122816B2Long acting peptide tyrosine tyrosine (PYY) analogs and methods of useINTARCIA THERAPEUTICS INC·Filed 2023·Granted Oct 22, 2024·0 cites·25 claims
- 1075US2025084142A1Long acting peptide tyrosine tyrosine (pyy) analogs and methods of useI2O THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1173US2025034225A1Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of useI2O THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1270US9133260B2GIP analog and hybrid polypeptides with selectable propertiesAMYLIN PHARMACEUTICALS LLC·Filed 2013·Granted Sep 15, 2015·1 cites·8 claims
- 1368US9441023B2Peptide YY analogsGLAXOSMITHKLINE IP DEV LTD·Filed 2014·Granted Sep 13, 2016·1 cites·38 claims
- 1468US7928060B2Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using themAMYLIN PHARMACEUTICALS INC·Filed 2005·Granted Apr 19, 2011·1 cites·16 claims
- 1566US12084485B2Long acting glucagon like polypeptide-1 (GLP-1) receptor agonists and methods of useINTARCIA THERAPEUTICS INC·Filed 2021·Granted Sep 10, 2024·0 cites·28 claims
- 1666US12018059B2Human amylin analog polypeptides and methods of useINTARCIA THERAPEUTICS INC·Filed 2019·Granted Jun 25, 2024·0 cites·35 claims
- 1755US8895498B2GIP and exendin hybrid polypeptidesLEVY ODILE ESTHER·Filed 2012·Granted Nov 25, 2014·0 cites·6 claims
- 1851US2024228572A1Long acting glucagon receptor selective peptides and methods of useI2O THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1948US2013281374A1Dpp-iv resistant gip hybrid polypeptides with selectable propertiesASTRAZENECA PHARMACEUTICALS LP·Filed 2013·Application pending·0 cites
- 2045US2010009907A1Glucagon-Like Peptides and Uses ThereofAMYLIN PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 2145US2010029554A1Composition and Methods for Treatment of Congestive Heart FailureAMYLIN PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 2243US2014249076A1Amylin-calcitonin chimeric peptides conjugated to duration enhancing moietiesAMYLIN PHARMACEUTICALS LLC·Filed 2012·Application pending·0 cites
- 2341US2009209460A1Compositions and methods for treating obesity and related metabolic disordersAMYLIN PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 2438US12427212B2Nectin-4 binding miniproteins, conjugates and uses thereofAKTIS ONCOLOGY INC·Filed 2025·Granted Sep 30, 2025·0 cites·30 claims
Join the waitlist — get patent alerts
Get an alert when Ved P. Srivastava files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →